• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Immutep Ltd. Announces Positive Phase II Trial Results for Eftilagimod Alfa in Soft Tissue Sarcoma
11:07
Oct29
Immutep Ltd. Shows Progress in LAG-3 Immunotherapy
06:49
Sep26
Analyst Storey Covers Healthcare Sector With Focus On Immutep Ltd
05:06
Aug29
Immutep released FY2025 Q4 earnings on August 28 (EST), actual revenue USD 618.59 K, actual EPS USD -0.0873
03:00
Immutep released FY2025 Q3 earnings on August 28 (EST), actual revenue USD 596.03K, actual EPS USD -0.0841
03:00
Immutep released FY2025 Annual Earnings on August 28 (EST), actual revenue USD 3.27 M (forecast USD 3.016 M), actual EPS USD -0.2735 (forecast USD -0.2392)
03:00

Schedules & Filings

Schedules
Filings
Aug28
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 618.59 K, Net Income -12.74 M, EPS -0.0873

Feb26
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 979.06 K, Net Income -6.96 M, EPS -0.0479

Aug29
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 577.35 K, Net Income -7.167 M, EPS -0.059

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SMX
462.270
+227.85%
+321.270
WHLR
5.460
+68.52%
+2.220
TGL
11.160
+65.14%
+4.402
TWNP
1.809
+58.71%
+0.670
TDIC
0.4180
+48.86%
+0.137
IRBT
4.250
+40.26%
+1.220
GFR.RT
1.180
+38.82%
+0.330
PRAX
260.500
+37.13%
+70.530
CLIK
7.660
+34.39%
+1.960
TORO
5.530
+33.90%
+1.400
View More